TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy - Top-Institutions - MDSpire

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • By

  • Carolina Kessler

  • Melanie von Brandenstein

  • Niklas Klümper

  • Philipp Krausewitz

  • Enno Storz

  • Constantin Rieger

  • Laurenz Sperber

  • Pia Paffenholz

  • Yuri Tolkach

  • Ralph Wirtz

  • Markus Eckstein

  • Axel Heidenreich

  • Richard Weiten

  • September 1, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Translational Cancer Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Cancer Therapeutics

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Translational Medicine

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Cancer Biology

  • #5

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Genitourinary Oncology
    • Translational Research

Original Source(s)

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy

  • by Carolina Kessler, Melanie von Brandenstein, Niklas Klümper, Philipp Krausewitz, Enno Storz, Constantin Rieger, Laurenz Sperber, Pia Paffenholz, Yuri Tolkach, Ralph Wirtz, Markus Eckstein, Axel Heidenreich, Richard Weiten

  • September 1, 2025

Related Content

Kidney Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.

  • March 3, 2025

  • 1 min
Molecular Profiling, Prognostic Insights, and Immune Landscape Evaluation of NUDT16 in Clear Cell Renal Cell Carcinoma

Kidney Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2024.

  • November 4, 2024

  • 1 min